USFDA issues warning letter to Cipla for Goa manufacturing facility

Drug firm Cipla Ltd said that the US health regulator has issued a
warning letter to the company for its manufacturing facility in Goa.
The company further said that it remains committed to maintain highest
standards of compliance and will work closely with the agency to
comprehensively address all the observations.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-issues-warning-letter-to-cipla-for-goa-manufacturing-facility/articleshow/74312928.cms

Comments

Popular posts from this blog

NISER PhD Program Admission 2020-21 (Winter Session)

Data Analyst Jobs – Life Sciences Apply at Cognizant

Are hospitals prescribing the more expensive remdesivir instead of cheaper alternatives?